PerkinElmer, headquartered in Shelton, completed its acquisition of SimoTech, a manufacturing automation and GMP IT solutions provider to the life sciences industry, following the transaction's announcement on August 11, 2026.
Founded in 2011 and headquartered in Cork, Ireland, SimoTech supports half of the world's top 20 pharmaceutical and biotechnology companies, collaborating with life sciences organizations to develop, implement, and manage automation and digital manufacturing solutions that accelerate project execution and enhance operational performance while ensuring regulatory compliance. The acquisition expands PerkinElmer's life sciences solutions, which include OneSource integrated laboratory and digital solutions and Project Farma's manufacturing and engineering platform.
Michael Stubblefield, Chief Executive Officer, PerkinElmer, said, "By combining SimoTech's expertise in manufacturing automation and digital systems with the capabilities of OneSource and Project Farma, this acquisition creates a significant opportunity to build a differentiated, scaled platform for pharmaceutical services. We are excited to welcome SimoTech's exceptional team to the PerkinElmer family."
SimoTech's clients partner with the company to design, build, operate, and optimize critical process automation systems, delivering fast-track project delivery, operational efficiency, and manufacturing agility.
"The combination of OneSource, Project Farma and SimoTech creates a unique opportunity to strengthen our partnerships with leading innovators and reduce the time to market for life-changing therapies," said Anshul Mangal, President of PerkinElmer's Pharma Specialty Services business. "SimoTech's expertise in automation and IT systems is a natural complement to our capabilities, enabling us to support customers across the full drug development and manufacturing lifecycle. Together, we bring highly complementary capabilities that position us to deliver greater value to our customers, unlock new opportunities for growth, and realize the full potential of a differentiated, scaled pharmaceutical services platform."
